Evoke Pharma Total Current Liabilities 2012-2024 | EVOK

Evoke Pharma total current liabilities from 2012 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Evoke Pharma Annual Total Current Liabilities
(Millions of US $)
2023 $3
2022 $2
2021 $1
2020 $8
2019 $2
2018 $2
2017 $2
2016 $1
2015 $2
2014 $2
2013 $2
2012 $1
2011 $0
Evoke Pharma Quarterly Total Current Liabilities
(Millions of US $)
2024-06-30 $9
2024-03-31 $9
2023-12-31 $10
2023-09-30 $2
2023-06-30 $2
2023-03-31 $2
2022-12-31 $2
2022-09-30 $2
2022-06-30 $1
2022-03-31 $1
2021-12-31 $1
2021-09-30 $1
2021-06-30 $6
2021-03-31 $6
2020-12-31 $8
2020-09-30 $7
2020-06-30 $7
2020-03-31 $2
2019-12-31 $2
2019-09-30 $2
2019-06-30 $1
2019-03-31 $1
2018-12-31 $2
2018-09-30 $2
2018-06-30 $1
2018-03-31 $1
2017-12-31 $2
2017-09-30 $3
2017-06-30 $2
2017-03-31 $1
2016-12-31 $1
2016-09-30 $1
2016-06-30 $6
2016-03-31 $2
2015-12-31 $2
2015-09-30 $2
2015-06-30 $3
2015-03-31 $3
2014-12-31 $2
2014-09-30 $2
2014-06-30 $2
2014-03-31 $3
2013-12-31 $2
2013-09-30 $3
2013-06-30 $2
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.005B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.612B 24.14
BridgeBio Pharma (BBIO) United States $5.094B 0.00
Bausch Health Cos (BHC) Canada $3.435B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.352B 13.96
Supernus Pharmaceuticals (SUPN) United States $2.021B 27.52
Taysha Gene Therapies (TSHA) United States $0.307B 50.00
Personalis (PSNL) United States $0.241B 0.00
Assembly Biosciences (ASMB) United States $0.106B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Teligent (TLGT) United States $0.000B 0.00